## Check for updates

## OPEN ACCESS

EDITED AND REVIEWED BY Diana Boraschi, Chinese Academy of Science (CAS), China

\*CORRESPONDENCE Dunfang Zhang izdf@163.com Hiroko Nakatsukasa nakatsukasa@chiba-u.jp

RECEIVED 30 April 2023 ACCEPTED 30 May 2023 PUBLISHED 06 June 2023

#### CITATION

Zhang D, Xu J, Wang Z and Nakatsukasa H (2023) Editorial: Oral mucosal immunity: homeostasis and inflammation. *Front. Immunol.* 14:1214926. doi: 10.3389/fimmu.2023.1214926

## COPYRIGHT

© 2023 Zhang, Xu, Wang and Nakatsukasa. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

# Editorial: Oral mucosal immunity: homeostasis and inflammation

# Dunfang Zhang<sup>1\*</sup>, Junji Xu<sup>2,3</sup>, Zhi Wang<sup>4</sup> and Hiroko Nakatsukasa<sup>5\*</sup>

<sup>1</sup>Department of Biotherapy, State Key Laboratory of Biotherapy and Cancer Center, Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, China, <sup>2</sup>Laboratory of Tissue Regeneration and Immunology and Department of Periodontics, Beijing Key Laboratory of Tooth Regeneration and Function Reconstruction, School of Stomatology, Capital Medical University, Beijing, China, <sup>3</sup>Immunology Research Center for Oral and Systemic Health, Beijing Friendship Hospital, Capital Medical University, Beijing, China, <sup>4</sup>Hospital of Stomatology, Guanghua School of Stomatology, Guangdong Provincial Key Laboratory of Stomatology, and Zhongshan School of Medicine, Sun Yat-Sen University, Guangzhou, Guangdong, China, <sup>5</sup>Laboratory of Microbiology and Immunology, Graduate School of Pharmaceutical Sciences, Chiba University, Chiba, Japan

### KEYWORDS

oral immunity, immune homeostasis, oral mucosa, oral inflammatory disorder, oral inflammation

## Editorial on the Research Topic

Oral mucosal immunity: homeostasis and inflammation

As the opening of the digestive tract, the on-going mechanical damage caused by chewing leads to continual inflammatory challenges and sustained immune responses to oral microorganisms and food (1). Oral mucosal inflammatory diseases, including infectious diseases (e.g. gingivitis, oral candidiasis, and oral herpes) and non-infectious inflammatory diseases (e.g. oral lichen planus (OLP) and recurrent aphthous ulcer (RAU)) are common and frequently occurring diseases of oral mucosa and may seriously affect our oral health. Besides, many systemic inflammatory diseases have typical oral inflammation phenotypes. During the past decade, a number of key progresses have been made in the study of oral mucosal immune homeostasis and diseases (2). By now, it has been well proven that oral mucosal immunity could affect the immune responses in the gastric intestinal tract and throughout the whole body (3). Thus, the goal of this Research Topic is to collect the latest research advances regarding the regulation of oral mucosal immunity in health and disease. To this end, we hosted 13 original research articles, review articles, and mini reviews.

Oral ulcer is the most common inflammatory disease in the oral cavity. To investigate whether N6-methyladenosine (m6A)-related single nucleotide polymorphisms (m6A-SNPs) are involved in the pathogenesis of oral ulcers, Wu et al. analyzed genome-wide association studies (GWAS) database and identified 11 m6A-SNPs that were related to oral ulcers, showing m6A RNA transcription modification may be involved in the development of oral ulcers.

OLP is a chronic inflammatory disorder of the oral mucosa (4). The clinical symptoms of OLP and discoid lupus erythematosus (DLE) are very similar. Wang R. et al. summarized

the significant differences in the expression levels and genotype polymorphism of two cytokines, TNF- $\alpha$  and IL-10, in OLP and DLE. They concluded that differential genotypes of TNF- $\alpha$  and IL-10 could be an immunological diagnosis for these two diseases.

Currently, the treatment of OLP mainly relies on immunosuppressive drugs (5). It has been proven that the response of OLP patients to the common immunosuppressive therapy is heterogeneous (6). To predicate the effectiveness of immunosuppressive therapy in OLP, Xu et al. developed a workflow by acquiring image-based features in OLP. They found that the best performance prediction model built by logistic regression showed an accuracy of 90%. This model could provide a valuable reference for the choice of medication for the OLP clinical treatment. Besides traditional immunosuppressive drugs, novel immunotherapy approaches are gaining traction. Xue et al. found that regulatory T cell (Treg cell) therapy may be an effective new treatment strategy for oral inflammatory diseases such as OLP.

The oral cavity has a rich symbiotic microbiome, second only to that of the gut (3). Long et al. revealed that the microbiota might maintain oral homeostasis by reshaping the structure of the oral epithelial barrier and changing the function of molecular biology. Wang X. et al. investigated the association between gut microbiota alterations and recurrent aphthous ulcer (RAU), and they indicated that gut dysbacteriosis, microbial dysfunction and immune imbalance occurred in RAU patients.

The incidences of oral mucosal inflammatory diseases are associated with a variety of systemic diseases (7). Zhang et al. found that the prevalence of Hashimoto's thyroiditis (HT) in OLP patients, especially in female OLP patients, is significantly higher than that in the general population. Li et al. reviewed the findings between oral mucosal inflammation and ulcerative colitis (UC), and they concluded that pyostomatitis vegetans, RAU and periodontitis, could not only be used to be risk factors for disease occurrence of UC, but also could be used to predict disease severity of UC. More than that, Seidel et al. investigated levels of inflammatory factors in newborns with orofacial clefts (OFC), and found that the expression of several inflammatory factors was increased than that of the healthy controls, suggesting that these children were at risk for oral mucosal inflammation.

So far, the pathogenesis of various oral mucosal inflammatory diseases is still unclear. Epithelial-mesenchymal transition (EMT) is a crucial biological process in the pathogenesis of oral mucosal disorders. Meng et al. provided a comprehensive evaluation of type-2 EMT in chronically inflammatory oral mucosal disorders, and they believe that targeting EMT could be a promising novel strategy to treat oral mucosal disorders in the future. Besides EMT, cellular senescence caused tissue aging is also thought to be a key factor in oral inflammation. Villalobos et al. summarized the effects of aging on periodontal tissues, and concluded that it could cause the imbalance of the periodontium and periodontitis. Yue et al. summarized the studies of the senescence-associated secretory phenotype (SASP) in in oral immunity, and they found that SASP might play a pleiotropic role in the pathogenesis of oral immunity.

In addition to oral mucosa, the immune homeostasis of oral secretory glands such as salivary glands is also very important for health. Sjogren's syndrome (SS) is a chronic autoimmune disorder that seriously affects the quality of life of patients (8). Zhan et al. reviewed the pathogenesis and treatment of SS, and they emphasized that targeted drugs, low-side-effect drugs, and combination therapies should be the focus of future research.

In summary, this Research Topic collected the current advances regarding the oral mucosal immune regulation, oral mucosal inflammatory disease pathogenesis and novel therapy strategies. More and more evidence shows that oral mucosal immune homeostasis is not only indispensable for health of the oral cavity, but also important for systemic health. Future studies should focus on two aspects: one is to explore the relationship between oral mucosal immune homeostasis and systemic immune homeostasis; the other is to study how to apply the findings of oral mucosal immunopathogenesis and novel therapy strategies to clinical treatment.

# Author contributions

DZ and HN wrote the manuscript. All authors reviewed and edited the manuscript, and approved it for publication.

# Funding

DZ is supported by the National Natural Science Foundation of China (No. 81600876, 82171829), the Key Project of the Science and Technology Department of Sichuan Province (No. 22GJHZ0141), the 1-3-5 Project for Disciplines of Excellence, West China Hospital, Sichuan University (No. ZYYC21012), and the Fundamental Research Funds for the Central Universities (1082204112F26).

# Acknowledgments

DZ sincerely wants to commemorate Dr. Sang-A Park, who passed away suddenly in a car accident on January 22, 2018.

# Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

# Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

# References

1. Dutzan N, Abusleme L, Bridgeman H, Greenwell-Wild T, Zangerle-Murray T, Fife ME, et al. On-going mechanical damage from mastication drives homeostatic Th17 cell responses at the oral barrier. *Immunity* (2017) 46(1):133–47. doi: 10.1016/j.immuni.2016.12.010

2. Williams DW, Hajishengallis G, Moutsopoulos NM. Regional specification of oral mucosal immunity. *Sci Immunol* (2022) 7(72):eabp8632. doi: 10.1126/sciimmunol.abp8632

3. Kitamoto S, Nagao-Kitamoto H, Hein R, Schmidt TM, Kamada N. The bacterial connection between the oral cavity and the gut diseases. *J Dent Res* (2020) 99(9):1021–9. doi: 10.1177/0022034520924633

4. Wang H, Zhang D, Han Q, Zhao X, Zeng X, Xu Y, et al. Role of distinct CD4(+) T helper subset in pathogenesis of oral lichen planus. *J Oral Pathol Med* (2016) 45(6):385–93. doi: 10.1111/jop.12405

5. Zhang D, Wang J, Li Z, Zhou M, Chen Q, Zeng X, et al. The activation of NFkappaB in infiltrated mononuclear cells negatively correlates with treg cell frequency in oral lichen planus. *Inflammation* (2015) 38(4):1683–9. doi: 10.1007/s10753-015-0145-x

6. Chamani G, Rad M, Zarei MR, Lotfi S, Sadeghi M, Ahmadi Z. Efficacy of tacrolimus and clobetasol in the treatment of oral lichen planus: a systematic review and meta-analysis. *Int J Dermatol* (2015) 54(9):996–1004. doi: 10.1111/ijd.12925

7. Kleinstein SE, Nelson KE, Freire M. Inflammatory networks linking oral microbiome with systemic health and disease. *J Dent Res* (2020) 99(10):1131–9. doi: 10.1177/0022034520926126

8. Xu J, Wang D, Liu D, Fan Z, Zhang H, Liu O, et al. Allogeneic mesenchymal stem cell treatment alleviates experimental and clinical sjogren syndrome. *Blood* (2012) 120 (15):3142–51. doi: 10.1182/blood-2011-11-391144